Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference

Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference

Article content

media

CEO Joseph Tucker, Ph.D., to discuss Enveric’s pipeline and therapeutic opportunities in fireside chat and “NextGen Psychedelics” panel discussion

Article content

CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will participate in the Benzinga Psychedelics Capital Conference being held Thursday, April 13, 2023, at the Fontainebleau Miami Beach, Florida.

Article content

Details of Enveric’s participation are as follows:

Presentation Format:

Fireside Chat

Date:

Thursday, April 13, 2023

Time:

10:30 a.m. ET

Location:

Playbook Stage, Fontainebleau Miami

Presentation Format:

Panel

Title:

NextGen Psychedelics

Date:

Thursday, April 13, 2023

Time:

3:20 p.m. ET

Location:

Playbook Stage, Fontainebleau Miami

During the conference, Dr. Tucker will host individual one-on-one meetings with registered investors and potential partners, showcasing Enveric’s business and clinical development strategy particularly the Company’s planned Phase 1 study of its lead candidate, EB-373 in Australia later this year as well as recent corporate achievements and anticipated milestones.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust Intellectual Property portfolio of New Chemical Entities for specific mental health indications. Enveric’s lead program, the EVM201 Series, comprises next generation synthetic psilocybin analogues that are considered prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-373 – for the treatment of anxiety disorders. Enveric is also advancing its third generation of therapeutics, the EVM301 Series, to offer a holistic approach for treating central nervous system disorders. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.

See also  Charting the Global Economy: Recovery in China Gathers Pace

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” ”expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of not purely historical statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to successfully spin-off its cannabinoid assets; the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

See also  Donald Trump Would Like to Momentarily Pause This Campaign to Tell You How Good His Brain Is

View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005386/en/

logo

Contacts

Investor Relations
Tiberend Strategic Advisors, Inc.
Daniel Kontoh-Boateng
(862) 213-1398
dboateng@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com

Leave a Reply

Your email address will not be published. Required fields are marked *